Drug Type Small molecule drug |
Synonyms Pelubi, Pelubiprofen (JAN/INN), 培比洛芬 + [8] |
Target |
Mechanism COX inhibitors(Cyclooxygenases inhibitors) |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date KR (01 Dec 2008), |
Regulation- |
Molecular FormulaC16H18O3 |
InChIKeyAUZUGWXLBGZUPP-GXDHUFHOSA-N |
CAS Registry69956-77-0 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Back Pain | KR | 01 Dec 2008 | |
Osteoarthritis | KR | 01 Dec 2008 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rheumatic Diseases | Phase 2 | US | - | |
Rheumatic Diseases | Phase 2 | JP | - | |
Primary dysmenorrhea | Preclinical | - | 30 Sep 2020 | |
Wounds and Injuries | Preclinical | KR | 25 Feb 2019 | |
Back Pain | Preclinical | - | 01 Apr 2014 | |
Acute upper respiratory infection | Preclinical | KR | 01 Jan 2013 | |
Fever | Preclinical | KR | 01 Jan 2013 | |
Musculoskeletal Pain | Preclinical | KR | - | |
Rheumatoid Arthritis | Preclinical | KR | - | |
Acute Pain | Discovery | KR | - |